Back to Search Start Over

Cystatin C and Cardiovascular Disease

Authors :
Heribert Schunkert
Wolfgang Koenig
Jessica van Setten
Meena Kumari
Johan Ärnlöv
J. Wouter Jukema
Vinicius Tragante
Alanna C. Morrison
Bradford B. Worrall
Brendan J. Keating
Alexander Teumer
Vilmantas Giedraitis
Tom Wilsgaard
Nilesh J. Samani
Barbara Thorand
Patricia B. Munroe
Rainer Malik
Melanie Waldenberger
Christopher P. Nelson
Sebastian E. Baumeister
Aroon D. Hingorani
Stéphanie Debette
Tove Fall
Patrik K. E. Magnusson
Nora Franceschini
Anders Larsson
Andrew P. Morris
Folkert W. Asselbergs
Maryam Kavousi
Oscar H. Franco
Jeanette Erdmann
Jonathan Marchini
Mika Kivimäki
Ivana Išgum
Fotios Drenos
N. Charlotte Onland-Moret
Bjørn Odvar Eriksen
Aicha Soumare
Christopher J. O'Donnell
Ingrid Toft
Paul I.W. de Bakker
Johannes Arpegård
Jacqueline de Graaf
Abbas Dehghan
Delilah Zabaneh
Michael V. Holmes
Yvonne T. van der Schouw
Alexander P. Reiner
André G. Uitterlinden
Christa Meisinger
Janine F. Felix
Erik Ingelsson
Lars Lind
Martin Dichgans
Marcus Dörr
Albert Hofman
Sanaz Sedaghat
Lambertus A. Kiemeney
Joshua C. Bis
Jens Baumert
Tessel E. Galesloot
Hester M. den Ruijter
Gerard Pasterkamp
Annette Peters
Naveed Sattar
Nancy L. Pedersen
Pim van der Harst
Stella Trompet
Per Svensson
Riyaz S. Patel
Philippe Amouyel
Sander W. van der Laan
Source :
Journal of the American College of Cardiology. 68:934-945
Publication Year :
2016
Publisher :
Elsevier BV, 2016.

Abstract

BACKGROUND Epidemiological studies show that high circulating cystatin C is associated with risk of cardiovascular disease (CVD), independent of creatinine-based renal function measurements. It is unclear whether this relationship is causal, arises from residual confounding, and/or is a consequence of reverse causation. OBJECTIVES The aim of this study was to use Mendelian randomization to investigate whether cystatin C is causally related to CVD in the general population. METHODS We incorporated participant data from 16 prospective cohorts (n = 76,481) with 37,126 measures of cystatin C and added genetic data from 43 studies (n = 252,216) with 63,292 CVD events. We used the common variant rs911119 in CST3 as an instrumental variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, ischemic stroke, and heart failure. RESULTS Cystatin C concentrations were associated with CVD risk after adjusting for age, sex, and traditional risk factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence interval [CI]: 1.56 to 2.13; p = 2.12 x 10(-14)). The minor allele of rs911119 was associated with decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p = 5.95 x 10(-211)), explaining 2.8% of the observed variation in cystatin C. Mendelian randomization analysis did not provide evidence fora causal role of cystatin C, with a causal relative risk for CVD of 1.00 per doubling cystatin C (95% CI: 0.82 to 1.22; p = 0,994), which was statistically different from the observational estimate (p = 1.6 x 10(-5)). A causal effect of cystatin C was not detected for any individual component of CVD. CONCLUSIONS Mendelian randomization analyses did not support a causal role of cystatin C in the etiology of CVD. As such, therapeutics targeted at lowering circulating cystatin C are unlikely to be effective in preventing CVD. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license.

Details

ISSN :
07351097
Volume :
68
Database :
OpenAIRE
Journal :
Journal of the American College of Cardiology
Accession number :
edsair.doi.dedup.....349129f2fcbb5bbfe6775dc918b081b3